HKSE •
Healthcare •
Drug Manufacturers - General •
Quote as of 09/18/2026 16:08
Company Profile
IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeHKSE
Market Capitalization3,186.17 mln
Float117 mln
Earnings Date08/31/2026
1-Year Forecast
31.89
Transformational upside
Relative Strength
5
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
Pre-Tax Margin
-774%
Severely loss-making
ROA
-83.32
Deeply negative
Business Description
Founded in Shanghai in 2009, IMPACT Therapeutics discovers and develops targeted cancer drugs that work by exploiting specific weaknesses in tumor cells, a strategy known as synthetic lethality. Its lead product, Senaparib, is approved for treating ovarian cancer, while several other drug candidates are currently being tested in clinical trials for various advanced solid tumors. The company is also advancing a broader portfolio of early-stage compounds with the goal of expanding treatment options for cancer patients across China and beyond.
